Less intensive long-term transfusion therapy for sickle cell anemia and cerebrovascular accident.
To determine the efficacy of a less intensive transfusion regimen in preventing recurrent cerebrovascular accidents and reducing transfusion requirements in patients with sickle cell anemia, we offered to 14 patients who had been undergoing aggressive transfusion therapy (sickle hemoglobin concentration kept less than 30% of total) for a mean of 9 years the option of either diminishing or stopping transfusion therapy. Thirteen patients chose to continue a modified transfusion regimen to maintain sickle hemoglobin concentration less than 60%; 10 of these patients have now been followed for 1 year or more (12 to 27 months, mean 15.5 months). There have been no recurrent neurologic events, although two patients have died of complications of hemochromatosis. All patients had a reduction in donor exposure, and there was a mean reduction in net transfusion requirement of 31.4% during the first year after modification. The greatest reduction was achieved in the single patient managed by small-volume (5 ml/kg) simple transfusion rather than partial packed cell exchange. We conclude that although long-term consequences of less aggressive transfusion therapy are unknown, the use of such a regimen may be reasonable, particularly in patients with significant transfusional hemochromatosis.
Miller
S T
ST
Department of Pediatrics, State University of New York Health Science Center, Brooklyn 11203.
Jensen
D
D
Rao
S P
SP
D000293:Adolescent; D000755:Anemia, Sickle Cell / Q000097:blood / Q000628:therapy*; D016913:Blood Component Transfusion; D001803:Blood Transfusion / Q000379:methods*; D002561:Cerebrovascular Disorders / Q000517:prevention & control*; D002648:Child; D002675:Child, Preschool; D002985:Clinical Protocols; D005078:Exchange Transfusion, Whole Blood; D005293:Ferritins / Q000097:blood; D006451:Hemoglobin, Sickle / Q000032:analysis; D006801:Humans; D012008:Recurrence; D012307:Risk Factors
D006451:Hemoglobin, Sickle; D005293:Ferritins